Keystone Symposia | Scientific Conferences on Biomedical and Life Science Topics

Tuberculosis: From Lab Research to Field Trials (C6)

Organizer(s): Stefan H.E. Kaufmann, Issar Smith and Carl F. Nathan
March 20 - 25, 2007
Fairmont Hotel Vancouver · Vancouver, British Columbia
Abstract Deadline: November 20, 2006
Late Abstract Deadline: December 20, 2006
Scholarship Deadline: November 20, 2006
Early Registration Deadline: January 22, 2007

Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation

The University of Colorado School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Colorado School of Medicine designates this educational activity for a maximum of 28-35 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

To receive CME credits, mark the box on the registration form, and pay the additional $50.00.

This meeting took place in the 2007 season.

For a complete list of the meetings for the upcoming/current season,
see our meeting list, or search for a meeting.

Summary of Meeting
Tuberculosis remains one of the major infectious disease killers in the world. This is in spite of the fact that, in most cases, the host response is capable of controlling Mycobacterium tuberculosis infection efficiently: only a minority of infected individuals develops active tuberculosis. The situation is exacerbated by increasing incidences of multi-drug-resistant strains and the dangerous liaison between tuberculosis and AIDS. Recent accomplishments in molecular genetics, cell biology, structural biology and immunology have provided the clues to an in-depth understanding of the crosstalk between pathogen and host which leads to latency, resuscitation, disease outbreak, susceptibility and protective immunity. Application of state-of-the-art technologies will help in elucidating underlying molecular mechanisms and in identifying the responsible gene products both on the side of the invader and its host. Based on such insights, novel vaccination strategies can be pursued and new drug candidates developed. This meeting will discuss the most recent findings in the broad field of research activities relevant to a better understanding of tuberculosis and provide a forum for intensive discussions and collaborations for scientists ranging from basic research to field studies. The meeting, therefore, will also promote exchange between and amalgamation of highly sophisticated research approaches and fundamental issues of disease control.

Objectives
Upon completion of this conference, participants should be able to:

To demonstrate an understanding of the latest developments in our knowledge of the metabolism, biochemistry and molecular genetics of Mycobacterium tuberculosis.
To analyze host response to M. tuberculosis infections, focusing on cellular and tissue responses, host genetic factors as determinants of disease and immune response and correlates of infection and disease.
To discuss the status of vaccine development against TB, including new candidate vaccines and booster strategies.
To describe the latest in anti-tubercular drug development, including the new use of existing compounds (fluoroquinolones) and new drugs with great potential (diaryl quinolones).

Tuesday, March 20
3:00 - 7:30 PM	Registration	BC Foyer
6:30 - 7:30 PM	Refreshments	Pacific Ballroom
7:30 - 8:30 PM	Keynote Address	British Columbia Ballroom


	Gerald H. Friedland, Yale University Extensively Drug Resistant TB (XDR-TB) in Rural South Africa - Tip of the Iceberg?
Wednesday, March 21
7:00 - 8:00 AM	Breakfast	Saturna/ Vancouver Island/ Pacific Ballroom
8:00 - 11:00 AM	Bacterial Metabolism and Biochemistry	British Columbia Ballroom
	Carl F. Nathan, Weill Cornell Medical College Selective Killing of Non-Replicating Mycobacteria by Inhibitors of Dihydrolipoamide Acyl Transferase
	Mamadou Daffé, Centre National de la Recherche Scientifique Biosynthesis and Function of Mycobacteria Cell Wall Components
	* Rajesh S. Gokhale, National Institute of Immunology Versatile Polyketide Enzymatic Machinery for Biosynthesis of Complex Mycobacterial Lipids

	David R. Sherman, Seattle Biomedical Research Institute Environmental Sensing and TB Metabolism
	Carlos Martin, University of Zaragoza Short Talk: Live Vaccines Based on phoP Mutants: A Step Toward Clinical Trials
9:20 - 9:40 AM	Coffee Break	BC Foyer
11:00 AM - 1:00 PM	Poster Setup	Pacific Ballroom
1:00 - 10:00 PM	Poster Viewing	Pacific Ballroom
2:30 - 4:30 PM	Workshop 1: Drugs against Tuberculosis	British Columbia Ballroom


	* Ann M. Ginsberg, Global Alliance For Tb Drug Development Recent Advances in TB Drug Development

	Barrington J. A. Furr, AstraZeneca Validated Targets and Antituberculosis Drug Discovery
	Vasan Sambandamurthy, Novartis Institute for Tropical Diseases A Chemical Genetics Approach to Identify Essential Targets in Mycobacterium tuberculosis

	Jacques H. Grosset, Johns Hopkins School of Medicine Current Problems and Possible Solutions for the Chemotherapy of Tuberculosis
	Douglas B. Young, Imperial College London Drugs for Treatment of Latent TB: a Grand Challenge in Global Health
4:30 - 5:00 PM	Coffee Available	BC Foyer
5:00 - 7:00 PM	Latency and Novel Intervention Strategies	British Columbia Ballroom
	Helena I. M. Boshoff, NIAID, National Institutes of Health Metabolism in Latent Tuberculosis
	Eric J. Rubin, Harvard School of Public Health Requirements for Mycobacterial Growth in vitro and in vivo

	Nicole Kruh, Colorado State University Short Talk: A Novel Interaction Between the FAS-II and PDIM Biosynthetic Pathways
	William Bishai, Johns Hopkins School of Medicine Modeling TB Pathogenesis: Have We Been Mouse Led?

7:00 - 8:00 PM	Social Hour w/ Lite Bites	Pacific Ballroom
7:30 - 10:00 PM	Poster Session 1	Pacific Ballroom
Thursday, March 22
7:00 - 8:00 AM	Breakfast	Saturna/ Vancouver Island/ Pacific Ballroom
8:00 - 11:00 AM	Functional and Structural Analysis on a Global Level	British Columbia Ballroom
	Issar Smith, Public Health Research Institute/ICPH Global Response of M. tuberculosis to the Environment
	* William R. Jacobs, Jr., Albert Einstein College of Medicine Eradicating Tuberculosis, A War on Two Fronts: Chemotherapy and Immune Evasion Mechanisms
	Lindsay D. Eltis, University of British Columbia Short Talk: Characterization of Cholesterol-Degrading Enzymes Critical for the Survival of Mycobacterium Tuberculosis in the Macrophage

	Brian D. Robertson, Imperial College London Look Global, Focus Local
	Matthias Wilmanns, European Molecular Biology Laboratory Hamburg Towards the Proteome of Mycobacterium Tuberculosis in 3D
9:20 - 9:40 AM	Coffee Break	BC Foyer
11:00 AM - 1:00 PM	Poster Setup	Pacific Ballroom
1:00 - 10:00 PM	Poster Viewing	Pacific Ballroom
2:30 - 4:30 PM	Workhop 2: Oral Abstract Presentations	British Columbia Ballroom
	* Camille Locht, Institut Pasteur de Lille From Extrapulmonary Dissemination to Diagnosis of Latent M. tuberculosis Infection and Novel Vaccine Development
	Marc Jacobsen, Bernhard-Nocht-Institute for Tropical Medicine Clonal Expansion of CD8+ Effector T Cells in Childhood Tuberculosis
	J. Muse Davis, University of Washington Mechanisms of Mycobacterial Dissemination Within and From Early Tuberculous Granulomas Revealed by Long-Term Live Imaging of Mycobacterium Marinum-Infected Zebrafish Embryos
	Anthony J. Hickey, University of North Carolina at Chapel Hill Needle-Free Vaccination by BCG-LPP Aerosols in the Guinea Pig
	Kari Ann Sweeney, Albert Einstein College Of Medicine A M. Tuberculosis Gene Cluster that Prevents IL-12 Induction and Innate Immune Killing
	Jeff E. Grotzke, Oregon Health & Science University The Mycobacterium Tuberculosis Phagosome: Evidence for ER-derived HLA-I Antigen Processing and Presentation
	Sandhya S. Visweswariah, Indian Institute of Science Cyclic AMP and Mycobacteria: Roles of Nucleotide Cyclases and Phosphodiesterases
4:30 - 5:00 PM	Coffee Available	BC Foyer
5:00 - 7:00 PM	Cell and Tissue Response	British Columbia Ballroom
	Sabine Ehrt, Weill Cornell Medical College Host Defense and Mycobacterial Virulence
	* Alan Sher, NIAID, National Institutes of Health Cellular Dynamics of Granuloma Formation and Maintenance Revealed by Intravital Imaging
	Hardy Kornfeld, University of Massachusetts Medical School Short Talk: Multiple Death Modes of M. tuberculosis-Infected Macrophages
	John D. MacMicking, Yale University Immunity-Related GTPases (IRGs) in Host Defense against Tuberculosis
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Pacific Ballroom
7:30 - 10:00 PM	Poster Session 2	Pacific Ballroom
Friday, March 23
7:00 - 8:00 AM	Breakfast	Saturna/ Vancouver Island/ Pacific Ballroom
8:00 - 11:00 AM	Genetic Determinants of Disease (Host and Pathogen)	British Columbia Ballroom
	* Peter M. Small, Bill & Melinda Gates Foundation
	Igor B. Kramnik, Boston University Experimental Mouse Model of Pulmonary Tuberculosis: Genetic Perspectives
	Laurent Abel, INSERM U550, Necker Medical School Human Genetics of Tuberculosis: A Continuous Spectrum of Predisposition
	Pedro O. Flores-Villanueva, University of Texas Health Center at Tyler MCP-1 Gene, Host Determinant of Progression from Infection to Disease
	Diane Houben, Netherlands Cancer Institute Short Talk: M. tuberculosis and M. leprae Translocate From the Phagolysosome to the Cytosol in Myeloid Cells
	Sebastien Gagneux, Medical Research Council, National Institute for Medical Research Evolution of Mycobacterium tuberculosis
9:20 - 9:40 AM	Coffee Break	BC Foyer
11:00 AM - 1:00 PM	Poster Setup	Pacific Ballroom
1:00 - 10:00 PM	Poster Viewing	Pacific Ballroom
2:30 - 4:30 PM	Workshop 3: Vaccines against Tuberculosis	British Columbia Ballroom
	Uli Fruth, World Health Organization What is Role of the World Health Organization in TB Vaccine Development?
	* Christine F. Sizemore, National Institutes of Health NIAID's Extramural TB Program - Contributions to TB Science and Vaccine Development
	Alexander von Gabain, Intercell Characterization of IC31TM, a Novel Multipurpose Adjuvant with a Profile Matching the Need of TB Vaccines
	Pascal Mettens, GlaxoSmithKline Prospects For Tuberculosis Vaccine Based On The Mtb72F/AS02A

	Francois Spertini, Centre Hospitalier Universitaire Vaudois Safety and Immunogenicity of the Mtb72F/AS02A Tuberculosis Vaccine in PPD-Positive Swiss Adults
	Albrecht Läufer, Vakzine Projekt Management GmbH Developing a TB Vaccine for Human Use
	Jerald C. Sadoff, Aeras Global TB Vaccine Foundation Aeras TB Vaccine Development
4:30 - 5:00 PM	Coffee Available	BC Foyer
5:00 - 7:30 PM	Immune Response and Correlates of Protection	British Columbia Ballroom
	* Gilla Kaplan, Public Health Research Institute, UMDNJ Immunologic Correlates of Protective Immunity against TB in BCG-Vaccinated Neonates
	Anne E. Goldfeld, Harvard Medical School Human Inflammatory Response Against M. tuberculosis
	Thomas H.M. Ottenhoff, Leiden University Medical Center Immunoregulation and Suppression in Human Tuberculosis
	David M. Lewinsohn, Portland VA Medical Center Short Talk: Defining Immunodominance in the Human CD8+ T Cell Response to Mtb
	Larry S. Schlesinger, Ohio State University Regulation of Lung Inflammation by Macrophages: Impact of the Alveolar Microenvironment on Tuberculosis Pathogenesis
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Pacific Ballroom
7:30 - 10:00 PM	Poster Session 3	Pacific Ballroom
Saturday, March 24
7:00 - 8:00 AM	Breakfast	Saturna/ Vancouver Island/ Pacific Ballroom
8:00 - 11:00 AM	Vaccines World TB Day. 125 Years after the Discovery of the Etiology of Tuberculosis	British Columbia Ballroom
	Stefan H.E. Kaufmann, Max Planck Institute for Infection Biology-Berlin Recombinant BCG with Improved Immunogenicity
	Peter Andersen, Statens Serum Institut Subunit Vaccines Against Tuberculosis
	* Marcus A. Horwitz, University of California, Los Angeles New More Potent and Safer Recombinant BCG Vaccines Against Tuberculosis
	Helen McShane, University of Oxford Boosting BCG with MVA85A - Results from Clinical Trials
9:20 - 9:40 AM	Coffee Break	BC Foyer
11:00 AM - 12:00 PM	Poster Setup	Pacific Ballroom
12:00 - 1:00 PM	Lunch	Pacific Ballroom/ Saturna/ Vancouver Island
1:00 - 5:00 PM	Poster Session 4	Pacific Ballroom/ Saturna/ Vancouver Island
4:30 - 5:00 PM	Coffee Available	BC Foyer
5:00 - 7:00 PM	Beyond the Wet Lab - Clinical Experience and Trials	British Columbia Ballroom
	Michael Levin, Imperial College London Insights into the Immunological Basis of Susceptibility and Resistance to Mycobacteria from Studies on Patients
	* Neil W. Schluger, Columbia University College of Physicians and Surgeons Tuberculosis Clinical Trials: Past, Present and Future
	Greg D. Hussey, University of Cape Town Development of a Tuberculosis Vaccine Trial Site in South Africa: Challenges and Lessons Learned
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Pacific Ballroom
8:00 - 11:00 PM	Entertainment	Pacific Ballroom
Sunday, March 25
	Departure

*Session Chair †Speaker invited, not yet responded.